Botulinum Neurotoxin Injection for Infraorbital Dark Circles
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Infraorbital dark circles are a significant cosmetic issue due to their impact on appearance and emotional well-being, with existing treatments like topical creams and makeup having limited efficacy.
Innovation Solution
Administration of botulinum neurotoxins, such as BOTOX®, to the dermal layer and muscle tissues around the orbital region to enhance blood flow and reduce vascular perfusion, thereby decreasing the appearance of dark circles by targeting neurosecretory substances like acetylcholine and calcitonin gene-related peptide.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical creams, lotions, oils, vitamins and makeup are used to treat infraorbital dark circles, then the appearance may be temporarily improved, but the efficacy is limited and does not provide lasting results
Solution Approach 1:
The patent changes the fundamental parameter of treatment from superficial topical applications to deep tissue injection therapy. By delivering botulinum toxin directly into the dermis and subcutaneous tissue, the treatment achieves lasting effects by modifying the underlying vascular and neural structures, rather than relying on temporary surface-level improvements from creams or makeup.
Solution Approach 2:
The patent replaces the mechanical/application-based approach of topical creams and lotions with a biological/neurological mechanism. Botulinum toxin blocks neurosecretory substance release at the neuromuscular junction, fundamentally changing how the treatment works from physical application to biological action, thereby achieving more reliable and durable results.
2Reliability
If botulinum neurotoxins are administered to block motor neurotransmission, then the appearance of dark circles is significantly improved, but the treatment requires injection procedures and carries potential risks
Solution Approach 1:
The patent uses botulinum toxin as an intermediary substance that mediates between the injection procedure and the desired cosmetic effect. The toxin serves as a carrier that, when injected, blocks neurosecretory substance release and thereby improves the appearance of dark circles, separating the invasive procedure from the beneficial outcome.
Solution Approach 2:
The patent changes the parameter of treatment delivery from non-invasive topical application to invasive injection therapy. This parameter change enables direct delivery of the active ingredient to the target tissue, achieving superior efficacy while accepting the increased procedural complexity and associated risks as a trade-off.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly reduces the appearance of infraorbital dark circles, improving the patient's emotional state and self-esteem, with effects lasting several months and potential combination with other therapies like dermal fillers for enhanced results.
Implementation Method 1
Botulinum neurotoxins (BoNTs) such as, for example, BoNT/A, BoNT/B, etc., act on the nervous system by blocking the release of neurosecretory substances such as neurotransmitters. The action of BoNT is initiated by its binding to a receptor molecule on the cell surface, then the toxin-receptor complex undergoes endocytosis. Once inside the cell, BoNT cleaves exocytotic specific proteins responsible for neurotransmitter docking and release from the cell known as the SNARE proteins
Implementation Method 2
The action of BoNT is initiated by its binding to a receptor molecule on the cell surface, then the toxin-receptor complex undergoes endocytosis
Implementation Method 3
Once inside the cell, BoNT cleaves exocytotic specific proteins responsible for neurotransmitter docking and release from the cell known as the SNARE proteins (soluble N-ethylmaleimide-sensitive factor attachment protein receptor). The resulting transient chemodenervation has been utilized medically to block motor neurotransmission
Data Source
AI summary
Infraorbital dark circles can be treated by administration of a botulinum toxin to a patient. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of an eye of a patient with infraorbital dark circles.